Cardiovascular benefits and adverse effects of common herbal therapies

Cardiology Review

Volumn 21, Issue 7, 2004, Pages

  Cassetta, Julia A ^a   Valli, Georgianne ^a   Giardina, Elsa Grace V ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATROPINE; BELLADONNA ALKALOID; CAFFEINE; CLONIDINE; CRATAEGUS EXTRACT; DIGOXIN; EPHEDRA SINICA EXTRACT; GARLIC EXTRACT; GINSENG EXTRACT; HELLEBORE EXTRACT; LICORICE EXTRACT; NERIUM OLEANDER EXTRACT; PLANT EXTRACT; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN; YOHIMBINE;

AGRANULOCYTOSIS; ANTIHYPERTENSIVE ACTIVITY; ASTHMA; BEHAVIOR CHANGE; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRAIN HEMORRHAGE; BRONCHOSPASM; BURN; CARDIOVASCULAR EFFECT; CONSUMER HEALTH INFORMATION; CRATAEGUS; DEATH; DIARRHEA; DIET SUPPLEMENTATION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; FLATULENCE; GARLIC; GASTRITIS; GASTROINTESTINAL SYMPTOM; GINSENG; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HERBAL MEDICINE; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LUNG EDEMA; MANIA; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; QUALITY CONTROL; REVIEW; SEIZURE; SIDE EFFECT; SKIN ALLERGY; SLEEP DISORDER; STROKE; TACHYCARDIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VERATRUM;

EID: 5144220305     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Brevoort P. The booming US botanical market; a new overview. Herbal Gram. 1998;4:33-46.
2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-1575.
3. Radimer KL, Subar AF, Thompson FE. Nonvitamin, nonmineral dietary supplements: issues and findings from NHANES III. J Am Diet Assoc. 2000; 100(4):447-454.
4. Cottrell K. Herbal products begin to attract the attention of brand-name companies. Can Med Assoc J. 1996;155(2): 216-219.
5. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355(9198):134-138.
6. Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998; 104(2):170-178.
7. Nahin RL, Straus SE. Research into complementary and alternative medicine: problems and potential. BMJ. 2001;322(7279):161-164.
8. Blumenthal M. Introduction. In: Blumenthal M, senior ed. The Complete German Commission E Monographs. Austin, Tex: American Botanical Council; 1998:5-80.
9. Fleming T, chief ed. PDR for Herbal Medicines. Montvale, NJ: Medical Economics Company, Inc; 2000:1.
10. Hesketh T, Zhu WX. Health in China. Traditional Chinese medicine: one country, two systems. BMJ. 1997;315 (7100):115-117.
11. Huang KC. The Pharmacology of Chinese Herbs. Boca Raton, Fla: CRC Press; 1993:3.
12. Agarwal KC. Therapeutic actions of garlic constituents. Med Res Rev. 1996; 16(1):111-124.
13. Ali M, Thomson M, Afzal M. Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance. Prostaglandins Leukot Essent Fatty Acids. 2000;62(2):55-73.
14. Lawson L. Garlic powder for hyperlipidemia - analysis of recent negative results. Q Rev Nat Med. 1998;187-189.
15. Das I, Khan NS, Sooranna SR. Potent activation of nitric oxide synthase by garlic: a basis for its therapeutic applications. Curr Med Res Opin. 1995;13(5): 257-263.
16. McMahon FG, Vargas R. Can garlic lower blood pressure? A pilot study. Pharmacotherapy. 1993;13(4):406-407.
17. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994;12(4):463-468.
18. Brace LD. Cardiovascular benefits of garlic (Allium sativum). J Cardiovasc Nurs. 2002;16(4):33-49.
19. Siegel RK. Ginseng abuse syndrome. JAMA. 1979;241(15):1614-1615.
20. Tauchert M, Gildor A, Lipinski J. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure [in German]. Herz. 1999;24(6): 465-474.
21. Nickerson M. Antihypertensive agents and the drug therapy of hypertension. In: Goodman LS, Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 3rd ed. New York, NY: The Macmillan Co; 1965:chap 33.
22. Onrot J, Goldberg MR, Biaggioni I, et al. Oral yohimbine in human autonomic failure. Neurology. 1987;37(2): 215-220.
23. Rose K, Croissant P, Parliament C, et al. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery. 1990;26(5): 880-882.
24. Ackermann RT, Mulrow CD, Ramirez G, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161(6):813-824.
25. German Commission E. Approved herbs. In: Blumentahal M, Busse WR, Goldberg A, et al, eds. The Complete German Commission E Monographs. Austin, Tex: American Botanical Council; 1998:73-418.
26. Sunter W. Warfarin and garlic. Pharmaceut J. 1991;722.
27. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol. 1999;58(11):1685-1693.
28. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf. 2002;25(5): 323-344.
29. Jaffe AM, Gephardt D, Courtemanche L. Poisoning due to ingestion of Veratrum viride (false hellebore). J Emerg Med. 1990;8(2):161-167.
30. Quatrehomme G, Bertrand F, Chauvet C, et al. Intoxication from Veratrum album. Hum Exp Toxicol. 1993;12(2):111-115.
31. Olukoga A, Donaldson D. Liquorice and its health implications. J Roy Soc Health. 2000;120(2):83-89.
32. Walker BR, Edwards CRW. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 1994; 23(2):359-377.
33. Hasegawa J, Suyama Y, Kinugawa T, et al. Echocardiographic findings of the heart resembling dilated cardiomyopathy during hypokalemic myopathy due to licorice-induced pseudoaldosteronism. Cardiovasc Drugs Ther. 1998;12(6):599-600.
34. Meadows M. Public health officials caution against ephedra use. FDA Consumer Magazine. May-June 2003. Available at: www.fda.gov/fdac/features/ 2003/303_ephedra.html.
35. Carlson M, Thompson RD. Liquid chromatographic determination of methylxanthines and catechins in herbal preparations containing guarana. J Assoc Off Anal Chem Int. 1998;81 (4):691-701.
36. Tyler VE. Herbs of Choice. Binghamton, NY: The Haworth Press, Inc; 1994:131.
37. Safadi R, Levy I, Amitai Y, et al. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Arch Intern Med. 1995;155 (19):2121-2125.
38. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, ed. in chief. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill; 1996: 199-248.
39. Musso NR, Vergassola C, Pende A, et al. Yohimbine effects on blood pressure and plasma catecholamines in human hypertension. Am J Hypertens. 1995;8(6):565-571.
40. de Smet PAGM, Smeets OSNM. Potential risks of health food products containing yohimbe extracts [letter]. BMJ. 1994;309(6959):958.
41. Chong SK, Oberholzer VG. Ginseng - is there a use in clinical medicine? Postgrad Med J. 1988;64(757):841-846.
42. Gillis CN. Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol. 1997;54(1):1-8.
43. Liberti LE, Der Marderosian A. Evaluation of commercial ginseng products. J Pharm Sci. 1978;67(10):1487-1489.
44. Han KH, Choe SC, Kim HS, et al. Effect of red ginseng on blood pressure in patients with essential hypertension and white coat hypertension. Am J Chin Med. 1998;26(2):199-209.
45. Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements. Drug Saf. 1997;17(5):342-356.
46. Becker BN, Greene J, Evanson J, et al. Ginseng-induced diuretic resistance. JAMA. 1996;276(8):606-607.
47. White LM, Gardner SF, Gurley BJ, et al. Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997;37(2):116-122.
48. Shekelle P, Hardy M, Morton SC, et al. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. Evidence Report/Technology Assessment No, 76 03-E022. Rockville, Md: Agency for Healthcare Research and Quality; 2003.
49. Zaacks SM, Klein L, Tan CD. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol. 1999; 37(4):485-489.
50. FDA announces rule prohibiting sale of dietary supplements containing ephedrine alkaloids effective April 12. FDA Statement. April 12, 2004. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01050.html.
51. Price LH, Charney DS, Heninger GR. Three cases of manic symptoms following yohimbine administration. Am J Psychiatry. 1984;141(10):1267- 1268.
52. Landis E, Shore E. Yohimbine-induced bronchospasm. Chest. 1989;96(6):1424.
53. Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology. 1993;41(4):343-345.
54. Siddiqui MA, More-O'Ferrall D, Hammond RS, et al. Agranulocytosis associated with yohimbine use [letter]. Arch Intern Med. 1996;156(11):1235-1236.
55. Heikens J, Fliers E, Endert E, et al. Liquorice-induced hypertension - a new understanding of an old disease: case report and brief review. Neth J Med. 1995;47(5):230-234.
56. Sigurjonsdottir HA, Ragnarsson J, Franzson L, et al. Is blood pressure commonly raised by moderate consumption of liquorice? J Hum Hypertens. 1995;9(5):345-348.